CS
VRDN icon

Candriam SCA’s Viridian Therapeutics VRDN Stock Holding History

Candriam SCA’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.3M Buy
1,707,698
+995,959
+140% +$16M 0.14% 149
2026
Q1 		$13.9M Sell
711,739
-73,359
-9% -$2.18M 0.07% 234
2025
Q4 		$24.4M Sell
785,098
-75,134
-9% -$2.06M 0.12% 168
2025
Q3 		$18.6M Sell
860,232
-2,041
-0.2% -$36.8K 0.1% 190
2025
Q2 		$12.1M Sell
862,273
-18,157
-2% -$246K 0.07% 221
2025
Q1 		$11.9M Buy
880,430
+149,209
+20% +$2.54M 0.07% 219
2024
Q4 		$14M Sell
731,221
-18,583
-2% -$404K 0.08% 218
2024
Q3 		$17.1M Hold
749,804
– – 0.1% 204
2024
Q2 		$9.75M Buy
749,804
+469,804
+168% +$6.5M 0.06% 254
2024
Q1 		$4.9M Buy
+280,000
New +$5.43M 0.03% 344

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Candriam SCA's VRDN Position: Q2 2026 in Review

Candriam SCA increased its Viridian Therapeutics (VRDN) stake by 140% in Q2 2026, buying an estimated $16M and bringing the position to 1,707,698 shares worth $31.3M. The position accounts for 0.14% of the portfolio, ranked #149.

Candriam SCA first reported a position in VRDN in Q1 2024 and has held it in 10 quarters since. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Candriam SCA held 1,707,698 shares of Viridian Therapeutics worth $31.3M as of Q2 2026.
  • Candriam SCA bought 995,959 Viridian Therapeutics shares in Q2 2026, an estimated $16M.
  • Viridian Therapeutics made up 0.14% of Candriam SCA's portfolio in Q2 2026, its #149 holding.
  • Candriam SCA first reported a position in Viridian Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.